A recent study reviewed advances in lentiviral vectors that expand utility for viral gene‑therapy applications, highlighting improvements in tropism, safety, and manufacturing. The research synthesized by Kaiser, Rouchka, and Smith documents vector engineering, pseudotyping strategies, and production process optimizations that aim to increase transduction efficiency while lowering insertional‑mutagenesis risk. The methodological updates have direct implications for clinical programs pursuing ex vivo and in vivo gene delivery. Biotech developers should consider vector choice and manufacturing scale‑up impacts on regulatory filings, long‑term follow‑up plans, and comparator safety expectations.